Argenx SE

Argenx SE is under investigation by Pomerantz Law Firm, potentially impacting its stock price and market performance.

Argenx SE, a biotech firm, is under investigation and facing scrutiny from investors and regulatory bodies due to concerns over its financial dealings and corporate governance.

Argenx SE has exceeded expectations with its half-year financial results, with EPS and revenue surpassing forecasts and its market capitalization now exceeding 30 billion euros.

Argenx SE is set to report its half-year 2025 financial results on July 31, 2025, as the biotech sector experiences positive trends despite the company’s relatively stable stock price.

Argenx SE will release its half-year 2025 financial results and second-quarter business update on July 31, 2025.

Argenx SE’s stock price has fluctuated amid regulatory scrutiny over its Vyvgart Hytrulo treatment, but analyst ratings have helped stabilize the stock.

Argenx SE’s stock price has declined due to the FDA’s evaluation of safety concerns surrounding its Vyvgart Hytrulo treatment.

Argenx SE’s approval of its subcutaneous treatment Vyvgart for CIDP has sparked debate over whether it’s a genuine breakthrough or market manipulation.

Argenx SE has secured European Commission approval for its VYVGART subcutaneous injection, a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), expanding its market reach to 27 EU countries.

Argenx SE has secured European Commission approval for its VYVGART treatment, a major milestone that could lead to significant growth, but investors have yet to take notice.